Amylyx prices $500M stock offering at $35.50 per share

Amylyx Pharmaceuticals announced the pricing of a $500 million stock offering at $35.50 per share. The company granted underwriters a 30-day option to purchase an additional 2,113,500 shares. Gross proceeds are projected to reach $500.2 million before accounting for underwriting fees and expenses. Amylyx plans to use the net proceeds for pre-commercial activities related to avexitide, such as securing manufacturing capacity, R&D, and working capital.

The offering is scheduled to close on or around Friday, pending customary closing conditions. Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital are serving as joint bookrunners. The shares are part of a shelf registration statement that became effective on March 3, 2026. A preliminary prospectus supplement and prospectus were filed with the SEC on Monday.

Amylyx specializes in investigational therapies for endocrine conditions and neurodegenerative diseases.